Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer: Hayward, California Tuesday, July 15, 2025, 13:00 Hrs [IST] Arcus Bioscience ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

HAYWARD, Calif.& TOKYO---- Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. today announced that Taiho exercised its option for quemliclustat, an investigational small molecule CD73 ...

Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported ...

Quemliclustat has been shown to block the production of adenosine. Once the immunosuppressive effects of adenosine are removed, activation of antitumor immune cells may be restored, resulting in ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

HAYWARD, Calif. & TOKYO, July 08, 2024--Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. ("Taiho") today announced that Taiho exercised its option for quemliclustat ...